window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 12, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

generalised myasthenia gravis

  • Central Nervous System,Clinical & Regulatory,Research & Development,Therapeutic Areas

    Zilucoplan accepted for eligible myasthenia gravis patients in NHS Scotland

    Zilucoplan has been accepted for restricted use in NHS Scotland [...]

    August 11, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Adneuris licenses cebranopadol to Maruishi in $35M Japan and South Korea deal
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • BlueWind wins FDA clearance for longer-lasting Revi implant for urinary incontinence
    Categories: Clinical & Regulatory, Medical devices, Therapeutic Areas
  • AI virtual screening tool boosts hit rate 100-fold on challenging drug targets
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top